Bradley Foster & Sargent’s AbbVie ABBV Stock Holding History

Bradley Foster & Sargent’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.5M	Sell	223,125 -4,880	-2%	-$1.08M	0.75%	39
2025 Q4	$52.1M	Sell	228,005 -3,151	-1%	-$718K	0.77%	36
2025 Q3	$53.5M	Sell	231,156 -1,560	-0.7%	-$318K	0.79%	35
2025 Q2	$43.2M	Buy	232,716 +432	+0.2%	+$80.3K	0.68%	42
2025 Q1	$48.7M	Sell	232,284 -3,014	-1%	-$586K	0.83%	35
2024 Q4	$41.8M	Sell	235,298 -3,076	-1%	-$566K	0.7%	39
2024 Q3	$47.1M	Sell	238,374 -5,938	-2%	-$1.11M	0.79%	37
2024 Q2	$41.9M	Sell	244,312 -1,215	-0.5%	-$201K	0.75%	38
2024 Q1	$44.7M	Sell	245,527 -6,756	-3%	-$1.16M	0.81%	38
2023 Q4	$39.1M	Sell	252,283 -5,248	-2%	-$765K	0.76%	40
2023 Q3	$34.7M	Hold	257,531	–	–	0.73%	43
2023 Q2	$34.7M	Sell	257,531 -263	-0.1%	-$38.6K	0.73%	43
2023 Q1	$41.1M	Sell	257,794 -3,136	-1%	-$479K	0.98%	31
2022 Q4	$42.2M	Sell	260,930 -181	-0.1%	-$27.8K	1.06%	30
2022 Q3	$35M	Buy	261,111 +4,146	+2%	+$595K	0.97%	32
2022 Q2	$39.4M	Sell	256,965 -988	-0.4%	-$151K	1.01%	31
2022 Q1	$41.8M	Buy	257,953 +7,079	+3%	+$1.03M	0.89%	33
2021 Q4	$34M	Buy	250,874 +29,150	+13%	+$3.44M	0.7%	42
2021 Q3	$23.9M	Buy	221,724 +8,170	+4%	+$934K	0.56%	55
2021 Q2	$24.1M	Buy	213,554 +18,205	+9%	+$2.05M	0.56%	52
2021 Q1	$21.1M	Buy	195,349 +18,112	+10%	+$1.94M	0.54%	56
2020 Q4	$19M	Buy	177,237 +6,899	+4%	+$663K	0.5%	59
2020 Q3	$14.9M	Buy	+170,338	New	+$16M	0.44%	61
2020 Q1	$11.6M	Buy	152,885 +4,963	+3%	+$423K	0.47%	61
2019 Q4	$13.1M	Sell	147,922 -519	-0.3%	-$43.1K	0.4%	68
2019 Q3	$11.2M	Sell	148,441 -8,425	-5%	-$578K	0.38%	74
2019 Q2	$11.4M	Buy	156,866 +11,332	+8%	+$891K	0.38%	71
2019 Q1	$11.7M	Sell	145,534 -13,197	-8%	-$1.08M	0.41%	69
2018 Q4	$14.6M	Sell	158,731 -2,906	-2%	-$256K	0.59%	56
2018 Q3	$15.3M	Sell	161,637 -972	-0.6%	-$92.2K	0.52%	61
2018 Q2	$15.1M	Buy	162,609 +54	+0%	+$5.27K	0.54%	58
2018 Q1	$15.4M	Sell	162,555 -871	-0.5%	-$95.7K	0.58%	56
2017 Q4	$15.8M	Buy	163,426 +1,421	+0.9%	+$134K	0.57%	59
2017 Q3	$14.4M	Sell	162,005 -1,889	-1%	-$144K	0.55%	61
2017 Q2	$11.9M	Sell	163,894 -1,178	-0.7%	-$79.2K	0.48%	63
2017 Q1	$10.8M	Sell	165,072 -3,117	-2%	-$196K	0.43%	72
2016 Q4	$10.5M	Buy	168,189 +5,533	+3%	+$338K	0.45%	74
2016 Q3	$10.3M	Sell	162,656 -1,375	-0.8%	-$89K	0.45%	74
2016 Q2	$10.2M	Sell	164,031 -15,639	-9%	-$953K	0.46%	70
2016 Q1	$10.3M	Sell	179,670 -3,110	-2%	-$173K	0.48%	66
2015 Q4	$10.8M	Sell	182,780 -1,882	-1%	-$108K	0.5%	72
2015 Q3	$10M	Sell	184,662 -2,125	-1%	-$138K	0.5%	70
2015 Q2	$12.6M	Buy	186,787 +2,592	+1%	+$169K	0.57%	63
2015 Q1	$10.8M	Buy	184,195 +3,090	+2%	+$187K	0.49%	71
2014 Q4	$11.9M	Buy	181,105 +9,018	+5%	+$569K	0.56%	65
2014 Q3	$9.94M	Sell	172,087 -35	-0%	-$1.94K	0.47%	74
2014 Q2	$9.71M	Buy	172,122 +4,350	+3%	+$228K	0.47%	70
2014 Q1	$8.62M	Buy	167,772 +8,174	+5%	+$413K	0.45%	72
2013 Q4	$8.43M	Buy	159,598 +4,785	+3%	+$235K	0.45%	69
2013 Q3	$6.92M	Buy	154,813 +6,521	+4%	+$289K	0.4%	74
2013 Q2	$6.13M	Buy	+148,292	New	+$6.49M	0.38%	78

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bradley Foster & Sargent's ABBV Position: Q1 2026 in Review

Bradley Foster & Sargent reduced its AbbVie (ABBV) stake by 2.1% in Q1 2026, selling an estimated $1.08M and leaving 223,125 shares worth $48.5M. The position accounts for 0.75% of the portfolio, ranked #39.

Bradley Foster & Sargent first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $53.5M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Bradley Foster & Sargent held 223,125 shares of AbbVie worth $48.5M as of Q1 2026.
Bradley Foster & Sargent sold 4,880 AbbVie shares in Q1 2026, an estimated $1.08M.
AbbVie made up 0.75% of Bradley Foster & Sargent's portfolio in Q1 2026, its #39 holding.
Bradley Foster & Sargent first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
Bradley Foster & Sargent's AbbVie position peaked at $53.5M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bradley Foster & Sargent's 13F filing for Q1 2026, filed 15 May 2026.